The Latest Urologic Oncology Journal Articles

Keep up to date with the latest in urologic oncology. Check out the latest diabetes articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily

• Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.4th May 2021
  Although prostate cancer is known to have a strong genetic basis and is influenced by both common and rare variants, the ability to investigate the combined effect of such genetic risk factors has been limited to date. We conducted an investigation of 81 094 men from the UK Biobank, including 3568 prostate cancer cases, to examine […]
• Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.28th April 2021
  Radiation refractory prostate cancer (RRPCa) is common and salvage cryotherapy for RRPCa is emerging as a viable local treatment option. However, there is a paucity of long-term data. The purpose of this study is to determine long-term outcomes following salvage cryotherapy for RRPca.Patients undergoing salvage cryotherapy for biopsy-proven, localized RRPCa from 1992 through 2004 were […]
• Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.28th April 2021
  The appropriate number of systematic biopsy cores to retrieve during Magnetic Resonance Imaging (MRI)-targeted prostate biopsy is not well defined. We aimed to demonstrate a biopsy sampling approach that reduces required core count while maintaining diagnostic performance.We collected data from a cohort of 971 men who underwent MRI-ultrasound fusion targeted biopsy for suspected prostate cancer. […]
• Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.27th April 2021
  Prostate cancer patients, who are scheduled for robot-assisted radical prostatectomy (RARP), often have a history of transurethral resection or laser enucleation of the prostate (TUR/LE-P) as treatment of benign prostate hyperplasia (BPH). We examined if these patients have impaired surgical, functional and oncological outcomes compared to those who have no symptom burden of moderate to […]
• Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum PSA.27th April 2021
  To determine if benign glandular tissue at the surgical margin (BGM) is associated with detectable PSA and/or biochemical recurrence (BCR) after radical prostatectomy (RP).Participants underwent RP for localized prostate cancer between 2004 and 2018. Regression analysis was used to identify demographic, clinical, and surgical factors associated with the likelihood of BGM presence on surgical pathology. […]
• The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.27th April 2021
  Although the Prostate Imaging-Reporting and Data System version 2 (PI-RADS v2) is a reliable diagnostic tool for significant prostate cancer (PCa), less is known about the prognostic significance of the structured reporting scheme for estimating oncologic outcomes after treatment. We aimed to synthesize the available evidence regarding the association of PI-RADS v2 score and risk […]
• Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.27th April 2021
  Atezolizumab is an anti-PD-L1 immune checkpoint inhibitor recommended for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy, regardless of PD-L1 status, among other treatment settings. We conducted a long-term follow-up to the exploratory analysis of overall survival (OS) and safety for the IMvigor211 intent-to-treat (ITT) population. Patients with mUC […]
• Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.27th April 2021
  To explore the association between genomic status and clinical outcome of platinum-based chemotherapy among patients with metastatic castration resistant prostate cancer (mCRPC).We conducted a retrospective study of 55 patients with mCRPC who received platinum-based chemotherapy after the progression to Docetaxel chemotherapy and underwent genomic profiling of 14 homologous recombination (HR) pathway genes. Progression free survival […]
• Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.23rd April 2021
  To assess whether PCa location might affect oncological outcomes after focal therapy (FT) for prostate cancer (PCa).We identified 274 men receiving FT for prostate cancer (PCa) using either HIFU or cryotherapy at a high volume centre between 2009 to 2018. Survival analyses using Kaplan Meier method were used to assess the any additional treatment and […]
• Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.23rd April 2021
  Intense neoadjuvant androgen deprivation therapy (ADT) before radical prostatectomy (RP) is an investigational approach to reduce recurrence rates in men with high-risk localized prostate cancer (PCa). The impact of germline DNA damage repair (gDDR) gene alterations on response to intense neoadjuvant ADT is not known.To evaluate the prevalence of gDDR alterations among men with localized […]
• A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS Score and Ethnicity in a Diverse, Multiethnic Population.21st April 2021
  Non-Hispanic Black (NHB) and Hispanic/Afro-Caribbean men have the highest risk for prostate cancer (PCa) compared to non-Hispanic White (NHW) men. However, ethnicity-specific outcomes of targeted fusion biopsy (FB) for the detection of PCa are poorly characterized. We compared the outcomes of FB by Prostate Imaging and Reporting Data System (PI-RADS) score and race/ethnicity among a […]
• Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on MRI for Targeted Biopsy.21st April 2021
  Targeted biopsy improves prostate cancer diagnosis. Accurate prostate segmentation on MRI is critical for accurate biopsy. Manual gland segmentation is tedious and time-consuming. We sought to develop a deep learning model to rapidly and accurately segment the prostate on MRI and to implement it as part of routine MR-US fusion biopsy in the clinic.905 subjects […]
• Risk Factors for Intravesical Recurrence After Minimally Invasive Nephroureterctomy for Upper Tract Urothelial Cancer (Robuust Collaboration).21st April 2021
  Intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) has an incidence of approximately 20-50%. Studies to date have been composed of mixed treatment cohorts – open, laparoscopic, and robotic. The objective of this study is to assess clinicopathologic risk factors for intravesical recurrence after RNU for UTUC in a completely […]
• Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).19th April 2021
  The comparative cardiovascular risk profiles of available hormone therapies for the treatment of prostate cancer is not known.We queried the FDA Adverse Event Reporting System (FAERS), a retrospective, pharmacovigilance database, for cardiovascular adverse event reports in men with prostate cancer receiving gonadotropin releasing hormone (GnRH) agonists, GnRH antagonists, androgen receptor antagonists, and/or androgen synthesis inhibitors […]
• Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy.19th April 2021
  According to the AUA/ASCO/ASTRO/SUO Guideline on treatment of nonmetastatic muscle-invasive bladder cancer (MIBC), females requiring radical cystectomy (RC) should undergo concomitant anterior pelvic exenteration despite low rates of malignant involvement of gynecologic organs. We present the clinicopathological characteristics of patients with MIBC treated with neoadjuvant chemotherapy (NAC) and evaluate the impact of NAC on gynecologic […]
• A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.12th April 2021
  Castration-resistant prostate cancer (CRPC) treatment is an evolving challenge. Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy (PRLT) with small-molecule, urea-based agents labeled with the β-particle-emitting radionuclide lutetium-177 (177Lu) is a promising new approach.In this systematic review and meta-analysis, we evaluated the efficacy and toxicity of PRLT.A systematic search was performed in PubMed/Medline (last updated February 18, […]
• Clinical Outcomes in Clinical N0 (cN0) Squamous Cell Carcinoma (SCC) of the Penis according to Nodal Management: Early, Delayed or Selective (following Dynamic Sentinel Node Biopsy – DSNB) Inguinal Lymph-Node Dissection (ILND).12th April 2021
  We evaluated the oncologic efficacy of early inguinal lymph-node dissection (ILND), observation or dynamic sentinel node biopsy (DSNB) followed by delayed or selective ILND in cN0 patients with penile squamous cell carcinoma (peSCC).Between 1980 and 2017 included, 296 evaluable consecutive cN0 peSCC patients underwent early ILND (16), observation (114) or DSNB (166). Median follow-up was […]
• Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.12th April 2021
  18F-Fluciclovine-based positron emission tomography (PET) imaging is recommended in the USA for biochemical recurrence (BCR) after prostate cancer treatment. However, prostate-specific membrane antigen (PSMA)-based PET imaging is more common worldwide, supported by international guidelines, and is now approved by the Food and Drug Administration in the USA for initial staging of primary prostate cancer. Little […]
• Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.11th April 2021
  Radiation therapy (RT) for prostate cancer (PCa) treatment is burdened by high rates of late urinary adverse events (UAEs). The feasibility of robot-assisted cystectomy (RAC) with intracorporeal urinary diversion (ICUD) for treatment of high-grade UAEs has never been assessed.To report perioperative outcomes, early (≤90 d) and late (>90 d) complications among patients undergoing RAC for […]
• Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.9th April 2021
  To report the preliminary results of salvage high-intensity focused ultrasound for locally recurrent prostate cancer in the prostatic bed after radical prostatectomy and adjuvant or salvage radiotherapy.We retrospectively analyzed a single-center cohort of men treated with salvage high-intensity focused ultrasound for locally recurrent prostate cancer after radical prostatectomy and adjuvant or salvage radiotherapy. All patients […]
• Stress Incontinence Surgery Does Not Cause Pelvic Malignancy: A Population-Based Cohort Study.8th April 2021
  We sought to determine if stress urinary incontinence surgery (mesh or nonmesh) is associated with the development of pelvic malignancies later in life.We performed a retrospective cohort study between January 1, 2002 and October 31, 2015 of all women in Ontario, Canada without a history of pelvic malignancy who underwent an index stress incontinence surgery. […]
• A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma.7th April 2021
  Identifying the most effective first-line treatment for metastatic renal cell carcinoma (mRCC) is challenging as rapidly evolving data quickly outdate the existing body of evidence, and current approaches to presenting the evidence in user-friendly formats are fraught with limitations.To maintain living evidence for contemporary first-line treatment for previously untreated mRCC.We have created a living, interactive […]
• Systematic Biopsy of the Prostate can Be Omitted in Men with PIRADS 5 and PSA Density Greater than 15.5th April 2021
  To evaluate the prostate cancer (PCa) and clinically significant PCa (CSPCa) detection on systematic (SB), target biopsy (TB) alone and combined SB and TB in men with Prostate Imaging Reporting and Data System (PIRADS)-5 lesion.From a prospectively maintained prostate biopsy (PBx) database, we identified consecutive patients with PIRADS 5 lesion on multiparametric magnetic resonance imaging […]
• Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.5th April 2021
  In general, the index lesion of prostate cancer has the largest tumor volume, the highest Grade Group (GG), and the highest stage (concordant cases). However these factors sometimes do not coincide within one lesion (discordant cases). In such discordant cases, the largest tumor may not be of biological significance and the secondary tumor may more […]
• Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.5th April 2021
  No published head-to-head randomized trials have compared the safety and efficacy of darolutamide versus apalutamide or enzalutamide in nonmetastatic castration-resistant prostate cancer. This study compares pre-specified adverse events and metastasis-free survival associated with darolutamide vs apalutamide, and darolutamide vs enzalutamide, via matching-adjusted indirect comparisons.Individual patient data from the phase III ARAMIS trial (NPLACEBO=553; NDAROLUTAMIDE=943) were […]
• Performance Feedback May Not Improve Radical Prostatectomy Outcomes: The Surgical Report Card (SuRep) Study.5th April 2021
  Oncologic, urinary, and sexual outcomes are important to patients receiving prostate cancer surgery. The objective of this study was to determine if providing surgical report cards (SuRep) to surgeons resulted in improved patient outcomes.A prospective before-and-after study was conducted at The Ottawa Hospital. 422 consecutive patients undergoing radical prostatectomy were enrolled. The intervention was provision […]
• Racial Disparities in PSA Screening and Referral to Urology in a Large, Integrated Healthcare System: A Retrospective Cohort Study.1st April 2021
  Contemporary trends and racial disparities in prostate cancer screening and referral to urology for prostate cancer (PCa) risk are not well characterized, despite consensus that Black men are at higher risk for poor PCa outcomes. The objective of this study was to characterize current racial disparities in PCa screening and referral from primary care to […]
• Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.31st March 2021
  In patients with muscle-invasive urothelial bladder cancer (MIBC), molecular alterations in immunotherapy-resistant tumors found at radical cystectomy (RC) remain largely unstudied.To investigate the biology of pembrolizumab-resistant tumors in comparison to an RC cohort treated without any systemic therapy and a cohort of neoadjuvant chemotherapy (NAC)-treated tumors.Transcriptome-wide expression profiling was performed on 26 RC samples from […]
• Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.31st March 2021
  Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) have shown lower rates of recurrence among patients with minimal residual disease after treatment. The molecular features that distinguish exceptional responders from poor responders are not known.To identify genomic and histologic features associated with […]
• Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.31st March 2021
  In addition to genetic alterations, epigenetic alterations play a crucial role during prostate cancer progression. A better understanding of the epigenetic factors that promote prostate cancer progression may lead to the design of rational therapeutic strategies to target prostate cancer more effectively.To systematically review recent literature on the role of epigenetic factors in prostate cancer […]
• No Outcome Differences after Cystectomy Between Patients with de Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study.30th March 2021
  Whether patients who progress to muscle-invasive bladder cancer (MIBC) have worse outcomes compared to those that present de novo is important for clinical decision-making. The objective of this study was to determine if there is a difference in survival after radical cystectomy for de novo cases compared to progressors.This retrospective, population-based study reports on all […]
• Active Surveillance for Risk Stratification of all Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.29th March 2021
  Despite general indolence of small renal masses (SRM) and no known adversity from treatment delays, broad usage of active surveillance (AS) as a means to risk-stratify SRM patients for more selective treatment has not been studied. We describe outcomes for a novel approach in which AS was recommended to all SRM patients lacking predefined progression […]
• Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).29th March 2021
  Men with low serum testosterone at the time of prostate cancer diagnosis are frequently considered to have more aggressive disease. We examined treatment outcomes in men with clinically localized high-risk cancer to determine if baseline testosterone level identified men at higher risk for cancer progression after treatment.Alliance/CALGB 90203 randomized men with clinically localized high-risk prostate […]
• Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.29th March 2021
  The primary advantage of en bloc resection of bladder tumors (ERBT) is to provide better diagnostic accuracy. However, the clinical significance of horizontal and vertical margin has not been demonstrated. We evaluated the clinical importance of surgical margins in patients who underwent ERBT.We retrospectively analyzed the records of 140 consecutive patients who underwent ERBT for […]
• Contemporary Trends and End-Results of National Institute of Health Grant Funding to Departments of Urology in the United States: A 10-year Analysis.29th March 2021
  To explore the patterns and distribution of National Institutes of Health (NIH) grant funding for Urologic research in the United States.The NIH RePORTER database was queried for all grants awarded to Urology Departments between 2010 and 2019. Information regarding the value of the grant, funded institution, successful publication of the research, and the category of […]
• Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally-Metastatic Prostate Cancer.29th March 2021
  To explore the genomic features of bone-only metastasis (bmPCa), hepatic metastasis (hmPCa) and pulmonary metastasis without liver involvement (pmPCa) in prostate cancer (PCa) using targeted next-generation sequencing.A hybridization capture-based next-generation sequencing was performed to detected genomic alterations in 50 genes, including androgen receptor (AR), DNA damage response (DDR) and other clinical relevant drivers.We successfully sequenced […]
• Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.12th March 2021
  Risk stratification for localized renal cell carcinoma (RCC) relies heavily on retrospective models, limiting their generalizability to contemporary cohorts.To introduce a contemporary RCC prognostic model, developed using prospective, highly annotated data from a phase III adjuvant trial.The model utilizes outcome data from the ECOG-ACRIN 2805 (ASSURE) RCC trial.The primary outcome for the model is disease-free […]
• Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.9th March 2021
  The hypothesis of a curable oligometastatic prostate cancer (PCa) state remains to be clinically-proven. Conventional imaging often fails to localize early recurrences, hampering the potential for radical approaches.We hypothesize that prostate-specific membrane antigen (PSMA)-targeted PET-MR/CT allows for earlier detection and localization of oligorecurrent-PCa, unveiling a molecularly-defined state amenable to curative-intent metastasis-directed treatment (MDT).Single-institution single-arm phase-two […]
• Association of Negative Follow-Up Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and meta-Analysis.8th March 2021
  With the growing adoption of active surveillance (AS) clinical parameters that can tailor the intensity of monitoring are increasingly needed. Therefore, we aimed to evaluate the prognostic value of negative follow-up biopsy for reclassification and upgrading in prostate cancer (PCa) patients managed with AS.The PubMed, Web of Science, and Scopus databases were queried to identify […]
• CD38 in Advanced Prostate Cancers.8th March 2021
  CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been elucidated.To characterise CD38 expression on prostate cancer (PC) epithelial cells and TIICs, and to associate this expression with clinical outcomes.RNAseq from 159 patients with […]
• Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma?8th March 2021
  Recent publications have reported an association between increased renal cancer-specific mortality (CSM) and reduced renal function “below safety limits,” and advocated for partial nephrectomy (PN) even for potentially aggressive/complex tumors. We hypothesize that this association may be related to confounding factors rather than a consequence of functional differences.To assess whether there is an independent association […]
• Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.8th March 2021
  The use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively.To evaluate the efficacy and safety of atezolizumab + bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with mRCC.IMmotion150 was a multicenter, randomized, open-label, phase 2 […]
• Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.8th March 2021
  We hypothesized that differences in active treatment rates may exist according race/ethnicity in favorable, as well as unfavorable intermediate risk (IR) prostate cancer (PCa).We relied on the Surveillance, Epidemiology and End Results (SEER) 18 database 2010-2015. We stratified according to three racial/ethnic groups (Caucasian vs. African American vs. Hispanic) and PCa baseline characteristics (PSA, clinical […]
• Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.8th March 2021
  This multicenter randomized phase 2 trial investigates the impact of intense androgen deprivation on radical prostatectomy (RP) pathologic response and radiographic and tissue biomarkers in localized prostate cancer (NCT02903368).Eligible patients had a Gleason score ≥4+3=7, PSA >20 ng/mL or T3 disease and lymph nodes <20 mm. In Part 1, patients were randomized 1:1 to apalutamide, […]
• Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.3rd March 2021
  Transurethral resection of bladder tumour (TURBT) is central to the diagnosis of muscle-invasive bladder cancer (MIBC). With the oncological safety of TURBT unknown, staging inaccuracies commonplace, and correct treatment of MIBC potentially delayed, multiparametric magnetic resonance imaging (mpMRI) may offer rapid, accurate, and noninvasive diagnosis of MIBC. BladderPath is a randomised trial comparing risk-stratified (5-point […]
• The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.3rd March 2021
  The feasibility and safety of robot-assisted radical cystectomy (RARC) may be undermined by unfavorable preoperative surgical characteristics such as previous prostate surgery (PPS).To compare perioperative outcomes for patients undergoing RARC with versus without a history of PPS.The study included 220 consecutive patients treated with RARC and pelvic lymph node dissection for bladder cancer at a […]
• A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).26th February 2021
  PSMA-targeted PET/CT has the potential to improve the detection and localization of prostate cancer (PCa). OSPREY was a prospective trial designed to determine the diagnostic performance of 18F-DCFPyL-PET/CT for detecting sites of metastatic PCa.Two patient populations underwent 18F-DCFPyL-PET/CT: Cohort A enrolled men with high-risk PCa undergoing radical prostatectomy with pelvic lymphadenectomy. Cohort B enrolled patients […]
• Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.22nd February 2021
  Salvage cystectomy is required for some patients with intravesical recurrence after trimodality therapy (TMT). We compared postoperative outcomes between salvage cystectomy post-TMT (SC), primary cystectomy (PC), and primary cystectomy with prior history of non-TMT abdominal or pelvic radiotherapy (PC with Hx XRT).265 patients were included who underwent radical cystectomy (RC) at Massachusetts General Hospital for […]
• Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.22nd February 2021
  Finasteride use has been associated with a reduced incidence of bladder cancer (BCa). However, the majority of studies have been conducted primarily in East Asian or Caucasian populations. Given differences in the incidence of BCa among racial/ethnic groups, it is important to determine whether the effect of finasteride use on BCa varies by race/ethnicity.We identified […]
• Restriction Spectrum Imaging-MRI to Improve Prostate Cancer Imaging in Men on Active Surveillance.22nd February 2021
  Restriction Spectrum Imaging (RSI-MRI) is a short duration enhanced diffusion weighted technique that seeks to standardize sequences and predict upgrading. We test this technology for active surveillance biopsies. Our objective is to investigate the utility of RSI-MRI to improve upgrading detection in a prostate cancer AS cohort.We prospectively enrolled men on AS undergoing repeat biopsy […]
• Risk-Based Selection for Active Surveillance: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.22nd February 2021
  To identify and validate known predictors of disease reclassification at 1 or 4 year(s) to support risk-based selection of patient suitable for AS.An individual participant data meta-analysis using data from 25 established cohorts within the Movember Foundations GAP3 consortium. In total 5,530 men were included. Disease reclassification was defined as any increase in Gleason grade […]
• Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.22nd February 2021
  Salvage lymph node dissection (sLND) is a rescue treatment for patients with nodal recurrence after radical prostatectomy (RP). Very limited data are available on robotic sLND. Our purpose was to investigate perioperative and oncological outcomes of robotic sLND in a large monocentric series.Perioperative data, complications within 30 d after surgery and oncological outcomes as assessed […]
• Specific Detection of Prostate Cancer Cells in Urine by RNA in Situ Hybridization.22nd February 2021
  Noninvasive tests that can accurately detect prostate cancer are urgently needed for prostate cancer diagnosis, surveillance, and prognosis. Exfoliated prostate cells captured in urine represent a promising resource for noninvasive detection of prostate cancer. We investigated performance of a novel cell-based urine test for detection of clinically significant prostate cancer.We previously developed a multiplex RNA […]
• Surveillance Intensity in Intermediate Risk Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.22nd February 2021
  To determine the optimal cystoscopic interval for intermediate-risk nonmuscle invasive bladder cancer (IR-NMIBC).A retrospective analysis of IR-NMIBC patients (2010-2017) was performed and 3 hypothetical models of surveillance intensity applied: Model 1: high (3-months), Model 2: moderate (6-months) and Model 3: low-intensity (12-months) over a 2-year period and we compared timing of actual detection of recurrence […]
• Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial.19th February 2021
  In men, complaints of nocturia causing poor sleep are often attributed to benign prostatic hyperplasia (BPH) and treated with BPH medications. We assessed whether treating lower urinary tract symptoms (LUTS) with dutasteride altered either nocturia or sleep quality using data from REDUCE.REDUCE was a 4-year randomized, multi-center trial comparing dutasteride 0.5mg/day vs. placebo for prostate […]
• Intraoperative Strategies to Reduce Catheter-Related Bladder Discomfort in the Early Postoperative Period after Robot-Assisted Radical Prostatectomy.19th February 2021
  Catheter-related bladder discomfort (CRBD) occurs in up to 63% of patients following robot-assisted radical prostatectomy (RARP). The optimal intra-operative anesthesia regime to prevent patients from CRBD is unknown.A prospective cohort analysis was conducted. Patients with biopsy-proven prostate cancer selected for RARP were included between January 2017 and April 2020 from a high-volume prostate cancer center. […]
• Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.14th February 2021
  Little is known about health-related quality of life (HRQOL) following treatment for bladder cancer (BC).To determine this, we undertook a cross-sectional survey covering 10% of the English population.Participants 1-10 yr from diagnosis were identified through national cancer registration data.A postal survey was administered containing generic HRQOL and BC-specific outcome measures. Findings were compared with those of […]
• Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.13th February 2021
  Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored.To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT.In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining […]
• A Systematic Review and Scoping Analysis of Smoking Cessation after a Urologic Cancer Diagnosis.12th February 2021
  Smoking cessation after a urologic cancer diagnosis significantly benefits patients. It is not well known how often patients quit after diagnosis or how urologists intervene to support patients’ smoking cessation efforts.To examine rates of smoking cessation after diagnosis among patients with urologic cancers and to assess how often patients are given advice and support to […]
• Micro-Ultrasound-guided Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.12th February 2021
  Micro-ultrasound is a novel, high-resolution, ultrasound technology, aiming to improve prostate imaging and, consequently, the diagnostic accuracy of ultrasound-guided prostate biopsy (PB). Micro-ultrasound-guided PB may present comparable detection rates to, the standard of care, multiparametric magnetic resonance imaging (mpMRI)-targeted PB for the diagnosis of clinically significant prostate cancer (PCa). We aimed to compare the detection […]